Advertisement

November 17, 2026

Radical’s Reperfusion Catheters Cleared for AIS

KEY TAKEAWAYS

  • The FDA granted 510(k) clearance for Radical Catheter Technologies’ 076 and 064 reperfusion catheters.
  • The devices are intended for mechanical thrombectomy in patients with acute ischemic stroke caused by large vessel occlusion.
  • The clearance expands Radical’s neurovascular catheter platform beyond access and delivery devices.

November 17, 2026—Radical Catheter Technologies, a NeuroTechnology Investors (NTI) portfolio company, announced that the FDA has granted 510(k) clearance for its Radical 076 and 064 reperfusion catheters.

According to Radical, the regulatory clearance marks an expansion of the company’s catheter platform beyond neurovascular access and delivery into mechanical thrombectomy devices intended for revascularization in patients experiencing acute ischemic stroke caused by a large vessel occlusion. Radical’s 6-, 7-, and 8-F neurovascular access catheters previously received FDA clearance.

The company stated that the reperfusion catheters build on Radical’s ribbon-based technology, which is designed to combine flexibility, stability, and durability in challenging neurovascular anatomy.

Benjamin Yim, MD, neurosurgeon at John Muir Medical Center in Walnut Creek, California, commented on the company’s technology in the press release.

“I’ve relied on the Radical access catheters for their trackability and support, so I was eager to try the new reperfusion catheter,” stated Dr. Yim. “The catheter tracked smoothly through tortuous anatomy, and I achieved complete revascularization on the first pass. It’s a natural extension of the platform, from access to reperfusion.”

Advertisement


November 17, 2026

Perfuze’s NeuroSheath 8-F Long Sheath Receives FDA Clearance

November 17, 2026

OCCLUDE Registry Data Published for Boston Scientific’s Obsidio Conformable Embolic


)